New Treatment Option for Those Looking to Help Stop Migraine Attacks Before They Start: Here’s What You Should Know

(BPT) - If you are one of the 39 million people affected by migraine in the U.S., you know that migraine is more than just a headache.1 Migraine can be a highly symptomatic and debilitating neurological disease that impacts three times as many women as men.2 Because migraines can be unpredictable, there is also the added stress of never knowing when, where, or how it will upend plans.3

Despite advances in the treatment of migraine, migraine disease remains misunderstood, underdiagnosed and undertreated.1 Treatment options are available to either help treat migraine attacks as they occur, or help prevent future attacks from occurring.2

The U.S. Food and Drug Administration (FDA) recently approved the first and only intravenous (IV) infusion migraine preventive treatment option that aims to help lower the occurrence of these attacks.4 The medication, VYEPTI™ (eptinezumab-jjmr), is administered by a healthcare provider four times per year (every three months) for the preventive treatment of migraine in adults.4 The recommended dose of VYEPTI is 100 mg, however, your doctor could decide that you may benefit from a 300 mg dose.4

Proven to reduce monthly migraine days beginning with the very first IV treatment, VYEPTI is designed to work fast.4 After each 30-minute infusion, 100 percent of the medication is available in the bloodstream.5

VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash, swelling of your face, lips, tongue, or throat, if you have trouble breathing, hives or redness in your face. Please see additional Important Safety Information below.

VYEPTI significantly reduces the number of monthly migraine days over the first three months and has shown sustained benefit through the second dose.4 In a one year study in adult patients with episodic migraine*, VYEPTI 100 mg reduced average monthly migraine days by 45 percent over months 1-3, compared to 33 percent with placebo.†6

More people were migraine free during a seven-day span following their first infusion with VYEPTI compared to placebo, most as soon as day one.4 On day one, there was a 52 percent reduction in the number of people experiencing a migraine, compared to 25 percent with placebo.7 Additionally, VYEPTI provided a treatment benefit that lasted through month six, compared to placebo, in patients that received two doses of VYEPTI.4

Talk to a doctor if you or a loved one suffers from migraine and learn more by visiting VYEPTI.com.

APPROVED USE

VYEPTI™ is a prescription medicine used for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.

VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash, swelling of your face, lips, tongue, or throat, if you have trouble breathing, hives or redness in your face.

Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.

These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Prescribing Information and Patient Information.

Talk to a doctor if you or a loved one suffers from migraine and learn more by visiting VYEPTI.com.

* Episodic migraine was defined as 4-14 headache days per month

VYEPTI 100 mg is the recommended dose, however, your doctor could decide that you may benefit from a 300 mg dose4

(C) 2020 Lundbeck. All rights reserved. VYEPTI is a trademark of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100050.



[1] Migraine Research Foundation. Migraine Facts. Available at https://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed February 19, 2020.

[2] Lipton RB, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349.

[3] Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619-6629. doi:10.1523/JNEUROSCI.0373-15.2015

[4] VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.

[5] Baker B, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020;00:e00567. https://doi.org/10.1002.prp2.567

[6] Data on File. Bothell, WA: Lundbeck Biopharmaceuticals, Inc.

[7] Ashina, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020, Vol. 40(3) 241-254. DOI: 10.1177/0333102420905132.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.